Aimmune Therapeutics, Inc. (NASDAQ:AIMT)
Industry: Healthcare

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. The company has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

Current Quote*
Last: $22.880
Change: 0.270
Book: $5.570
Volume: 555,527

As Of: 01/18 13:35 ET
*Quotes delayed by 20min.

Graphs for AIMT


3 Month Graph


6 Month Graph


1 Year Graph